Option Care Health, a major provider of home and alternate-site infusion services, is in advanced talks to be acquired in a deal that would value the company at more than $5 billion including debt, according to a report from the Financial Times. The potential buyers are McKesson, one of the largest US drug distributors, and Clayton Dubilier & Rice (CD&R), a private equity firm. The two are discussing a structure in which CD&R would take a 51% stake and McKesson would hold 49%.
While the talks are still ongoing and could fall apart, the reported structure offers a clear picture of how the deal might work—and what it would mean for the companies involved and for investors watching from the sidelines.
What the ownership split means
In the world of corporate deals, control often matters more than the size of a stake. At 51%, CD&R would hold a majority interest in Option Care Health, giving it the power to shape the company's direction. That includes decisions about the board of directors, how much debt the company takes on, and where it cuts costs or invests for growth. In practice, a majority owner can replace management, set strategy, and push through operational changes more quickly than a minority partner could.
McKesson's 49% stake, by contrast, would leave it as a significant but minority shareholder. That position would still give McKesson meaningful exposure to Option Care Health's home-infusion business—a growing segment of healthcare—without taking on the full integration work and balance-sheet burden of an outright acquisition. For McKesson, this could be a way to stay economically aligned with a fast-growing part of the healthcare market while letting a private equity firm take the lead on operational and financial restructuring.
This kind of structure—a private equity firm paired with a strategic partner—is not uncommon in healthcare deals. It allows the private equity firm to bring its playbook of cost-cutting and efficiency improvements, while the strategic partner provides industry expertise and potential synergies. The 51%-49% split signals that CD&R would be in the driver's seat, making this look more like a leveraged buyout than a traditional merger.
Why Option Care Health is attractive
Option Care Health operates in the home and alternate-site infusion market, which involves delivering intravenous medications and other therapies to patients in their homes or in outpatient clinics rather than in hospitals. This segment has been growing as healthcare providers and payers look for ways to reduce costs and move care out of expensive hospital settings. The company's services are used for a range of conditions, including chronic illnesses, infections, and nutritional support.
For McKesson, a major distributor of pharmaceuticals and medical supplies, a stake in Option Care Health could strengthen its position in the home-care channel, which is increasingly important as more care shifts to outpatient and home settings. For CD&R, the deal would represent another healthcare investment in a sector with steady demand and potential for operational improvements.
The reported valuation of more than $5 billion including debt suggests that the buyers see significant value in the company's cash flows and growth prospects. However, the final price and terms are still being negotiated, and there is no guarantee that a deal will be reached.
What it means for investors
For everyday investors, the key takeaway is that this deal, if completed, would likely put CD&R in control of Option Care Health. That means the company's future would be shaped by private equity priorities: reducing costs, improving margins, and eventually finding a way to exit the investment, possibly through a sale or a public listing.
One of the biggest questions in any leveraged buyout is how much debt the company will take on. If CD&R finances a large portion of the purchase with borrowed money, Option Care Health's balance sheet could become more leveraged, which could affect its credit rating and its ability to invest in growth. Investors who hold Option Care Health's bonds or who are considering buying its stock (if it remains public) should watch for details on the financing structure.
For shareholders of Option Care Health, the deal would likely mean a cash payout at a premium to the current stock price, assuming the deal closes. But deals of this size can take months to finalize, and there is always the risk that talks break down, as has happened with other high-profile mergers. For example, Sainsbury's and Morrisons held merger talks, then walked away, showing that even advanced discussions can collapse.
Investors should also consider the broader context. Healthcare services and distribution have been active areas for dealmaking, as companies seek to adapt to changing reimbursement models and the shift toward value-based care. Bayer's recent $2.2 billion investment in a new manufacturing site is another example of how healthcare companies are positioning for the future.
For now, the market will be watching for official confirmation from the companies involved. If the deal goes through, it could have ripple effects on McKesson's stock, as investors assess the strategic logic of a minority stake, and on Option Care Health's bond prices, which would react to the new ownership and financing plans.
In the meantime, this story is a reminder that in the world of takeovers, the structure of a deal can be just as important as the price. A 51%-49% split is not a typical merger; it's a private equity-led acquisition with a strategic partner attached. That distinction matters for anyone trying to understand what comes next for the companies involved.
